Pharmacology and the Nursing Process 10th Edition Test Bank - Coagulation Modifier Drugs Related

Review Pharmacology and the Nursing Process 10th Edition Test Bank - Coagulation Modifier Drugs related questions and content

A patient will be taking dabigatran as part of treatment for chronic atrial fibrillation. Which statements about dabigatran are true?

  • A. The dose of dabigatran is reduced in patients with decreased renal function.
  • B. Bleeding is the most common adverse effect.
  • C. Idarucizumab is given as an antidote in cases of uncontrolled bleeding.
  • D. Dabigatran levels are monitored by measuring prothrombin time/international normalized ratio (PT/INR) results.
  • E. This drug is a prodrug and becomes activated in the liver.
Correct Answer: A,B,C,E

Rationale: Dabigatran is excreted extensively in the kidneys, and the dose is dependent upon renal function. The normal dose is 150 mg twice daily, but it will be given at reduced dosage if renal impairment is present. The most common and serious side effect is bleeding. Dabigatran is a prodrug that becomes activated in the liver. Idarucizumab (Praxbind) is a specific dabigatran antidote that reverses the anticoagulant effects of dabigatran for emergency surgery or in life-threatening or uncontrolled bleeding. Dabigatran levels are not monitored by PT/INR.